topics / rare disease

Tagged rare disease.

Preliminary human SS-31 (Elamipretide): Real human trials, mostly failed endpoints, one narrow approval Elamipretide won a narrow FDA accelerated approval for Barth syndrome in 2025, but its largest trials in myopathy, heart failure, and dry AMD all missed.